Gene: KCNQ5

56479
Kv7.5|MRD46
potassium voltage-gated channel subfamily Q member 5
protein-coding
6q13
Ensembl:ENSG00000185760 MIM:607357 Vega:OTTHUMG00000015020 UniprotKB:Q9NR82
NG_047170.1
PubMed|SNP Mapped
2   ANCO-SNPs
ND|AD
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
3.825e-1 (AD)  1.134e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs12662682chr6:73180074 (GRCh38.p7)A>Galcohol dependenceSNV(Single Nucleotide Variation)
rs885247chr6:72950511 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
RBFOX10.984
GABRB20.978
ADAM230.976
FRMPD40.975
DLGAP10.973
AAK10.973
NMNAT20.973
ADD20.972
HCN10.971
CNKSR20.971

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MYL3-0.61
HEY2-0.599
RAB13-0.598
CSAG1-0.586
YES1-0.579
WWTR1-0.575
RNF135-0.573
CNN2-0.567
RAI14-0.563
TFPI2-0.561

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB04953EzogabineSmall Molecule150812-12-7Approved|InvestigationalTarget
DB06089ICA-105665Small Molecule-InvestigationalTarget
ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of KCNQ5 mRNA"25510870
C5112952,2',4,4'-tetrabromodiphenyl ether"2,2',4,4'-tetrabromodiphenyl ether results in increased expression of KCNQ5 mRNA"29112739
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of KCNQ5 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of KCNQ5 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of KCNQ5 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of KCNQ5 mRNA"25510870
D000082AcetaminophenAcetaminophen results in increased expression of KCNQ5 mRNA29067470
D000111Acetylcysteine[indole-3-carbinol co-treated with Diethylnitrosamine co-treated with Acetylcysteine] results in decreased expression of KCNQ5 mRNA22129741
D020106AcrylamideAcrylamide analog results in increased activity of KCNQ5 protein16904708
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of KCNQ5 gene27153756
D000643Ammonium ChlorideAmmonium Chloride affects the expression of KCNQ5 mRNA16483693
D001280AtrazineAtrazine results in decreased expression of KCNQ5 mRNA25929836
C547126AZM551248AZM551248 results in decreased expression of KCNQ5 mRNA22323515
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of KCNQ5 mRNA"20382639
D004958EstradiolEstradiol affects the expression of KCNQ5 mRNA22574217
C006780bisphenol Abisphenol A results in decreased expression of KCNQ5 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of KCNQ5 gene28505145
C026690cerous chloridecerous chloride results in increased expression of KCNQ5 mRNA23573234
D003042CocaineHDAC5 affects the reaction [Cocaine affects the expression of KCNQ5 mRNA]17988634
D004052Diethylnitrosamine[indole-3-carbinol co-treated with Diethylnitrosamine co-treated with Acetylcysteine] results in decreased expression of KCNQ5 mRNA22129741
D004997Ethinyl EstradiolESR1 gene mutant form inhibits the reaction [Ethinyl Estradiol results in increased expression of KCNQ5 mRNA]29112739
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of KCNQ5 mRNA29112739
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in decreased expression of KCNQ5 mRNA23649840
D005411Flame RetardantsESR1 gene mutant form inhibits the reaction [Flame Retardants results in increased expression of KCNQ5 mRNA]29112739
D005411Flame RetardantsFlame Retardants results in increased expression of KCNQ5 mRNA29112739
D005557FormaldehydeFormaldehyde results in decreased expression of KCNQ5 mRNA23649840
D006861Hydrogen PeroxideHydrogen Peroxide affects the expression of KCNQ5 mRNA20044591
C016517indole-3-carbinol[indole-3-carbinol co-treated with Diethylnitrosamine co-treated with Acetylcysteine] results in decreased expression of KCNQ5 mRNA22129741
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of KCNQ5 mRNA21889194|2479639
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of KCNQ5 mRNA23649840
C476437N-(1-(3-morpholin-4-ylphenyl)ethyl)-3-phenylacrylamideN-(1-(3-morpholin-4-ylphenyl)ethyl)-3-phenylacrylamide results in increased activity of KCNQ5 protein16904708
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of KCNQ5 mRNA"25510870
C027373potassium chromate(VI)potassium chromate(VI) results in increased expression of KCNQ5 mRNA22714537
D011441PropylthiouracilPropylthiouracil results in increased expression of KCNQ5 mRNA24780913
D052999QuinazolinonesQuinazolinones analog results in increased activity of [KCNQ3 protein binds to KCNQ5 protein]21723881
D052999Quinazolinones[Quinazolinones analog results in increased activity of [KCNQ3 protein binds to KCNQ5 protein]] which results in increased import of Thallium21723881
D052999QuinazolinonesQuinazolinones analog results in increased activity of KCNQ5 protein21723881
D052999Quinazolinones[Quinazolinones analog results in increased activity of KCNQ5 protein] which results in increased import of Thallium21723881
C009277sodium arsenatesodium arsenate results in increased expression of KCNQ5 mRNA21795629
C017947sodium arsenitesodium arsenite results in increased expression of KCNQ5 mRNA22714537
D013739TestosteroneTestosterone affects the expression of KCNQ5 mRNA20403060
D013793Thallium[KCNQ5 protein binds to KCNQ3 protein] which results in increased import of Thallium21723881
D013793ThalliumKCNQ5 protein results in increased import of Thallium21723881
D013793Thallium[Quinazolinones analog results in increased activity of [KCNQ3 protein binds to KCNQ5 protein]] which results in increased import of Thallium21723881
D013793Thallium[Quinazolinones analog results in increased activity of KCNQ5 protein] which results in increased import of Thallium21723881
D014212TretinoinTretinoin results in increased expression of KCNQ5 mRNA21934132
C005445triphenyl phosphate"ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of KCNQ5 mRNA]"29112739
C005445triphenyl phosphate"[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of KCNQ5 mRNA"29112739
C016805tris(1,3-dichloro-2-propyl)phosphate"ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of KCNQ5 mRNA]"29112739
C016805tris(1,3-dichloro-2-propyl)phosphate"[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of KCNQ5 mRNA"29112739
D014317Tritolyl Phosphates"ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of KCNQ5 mRNA]"29112739
D014317Tritolyl Phosphates"[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of KCNQ5 mRNA"29112739
D014635Valproic AcidValproic Acid results in increased expression of KCNQ5 mRNA28001369
D014638VanadatesVanadates results in decreased expression of KCNQ5 mRNA22714537

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005249voltage-gated potassium channel activity-IBA21873635  
GO:0005249voltage-gated potassium channel activity-IDA10787416  11159685  24855057  
GO:0005249voltage-gated potassium channel activity-IMP28669405  
GO:0005251delayed rectifier potassium channel activity-IBA21873635  
GO:0005515protein binding-IPI24855057  
GO:0005516calmodulin binding-IBA21873635  
GO ID GO Term Qualifier Evidence PubMed
GO:0034765regulation of ion transmembrane transport-IEA-  
GO:0071805potassium ion transmembrane transport-IBA21873635  
GO:0071805potassium ion transmembrane transport-IDA10787416  11159685  
GO:0071805potassium ion transmembrane transport-IMP28669405  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-TAS-  
GO:0005887integral component of plasma membrane-IDA10787416  11159685  
GO:0008076voltage-gated potassium channel complex-IBA21873635  
GO:0008076voltage-gated potassium channel complex-IDA10787416  11159685  
GO:0016021integral component of membrane-IBA21873635  
GO:0030118clathrin coat-IDA24855057  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-112316Neuronal SystemTAS
R-HSA-1296071Potassium ChannelsTAS
R-HSA-1296072Voltage gated Potassium channelsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
21314694Genomewide association analysis of symptoms of alcohol dependence in the molecular genetics of schizophrenia (MGS2) control sample. (2011 May)Kendler KSAlcohol Clin Exp Res
25672891A genome-wide association study of periodontitis in a Japanese population. (2015 Apr)Shimizu SJ Dent Res